An increase in glucocorticoid replacement therapy may be advisable in male patients affected by CAH presenting with growing TARTs to reduce ACTH levels, weighing such benefit against the risks of glucocorticoid excess. This evidence concerns the gene POMC and congenital adrenal hyperplasia.